Nilotinib: Optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib

Medicine & Life Sciences

• 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 82%
• Imatinib Mesylate 64%
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60%
• Phosphotransferases 14%
• 2-aminopyrimidine 11%
• Oncogene Fusion 10%
• Therapeutics 9%
• Dasatinib 8%
• Leukemia, Myeloid, Chronic Phase 8%
• Myeloid Progenitor Cells 8%
• Age Factors 7%
• Point Mutation 6%
• Standard of Care 6%
• Protein-Tyrosine Kinases 5%
• Survival 3%

Chemistry

• Nilotinib 100%
• Imatinib 85%
• Resistance 35%
• Aminopyrimidine 9%
• Tyrosine Kinase Inhibitor 8%
• Phosphotransferase Inhibitor 8%
• Mutation 5%